No quarterly revenue total was found in Immuneering Corporation's SEC filings.
Immuneering Corporation (IMRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.8 million. As of Sep 30, 2026 it held $58.2 million in cash and investments and $3.5 million in total debt.
Revenue
—
Net income
$-24.19M
-61.7% vs year-ago quarter
Operating cash flow
$-16.79M
-40.1% vs year-ago quarter
Free cash flow
$-16.80M
-40.2% vs year-ago quarter
EPS
$-0.37
+2.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
25.94M
Net cash
$54.69M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1790340
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$25.8M | -$19.0M | -$15.3M | -$13.8M | -$15.4M |
| Net income | -$24.2M | -$17.3M | -$13.5M | -$11.6M | -$15.0M |
| Diluted EPS | -$0.37 | -$0.27 | -$0.21 | -$0.18 | -$0.38 |
| Operating cash flow | -$16.8M | -$16.5M | -$18.4M | -$9.8M | -$12.0M |
| Free cash flow | -$16.8M | -$16.5M | -$18.5M | -$10.0M | -$12.0M |
| Total assets | $182.6M | $202.1M | $214.8M | $232.0M | $241.1M |
| Total liabilities | $13.9M | $11.3M | $8.3M | $13.5M | $13.1M |
| Stockholders' equity | $168.7M | $190.7M | $206.5M | $218.5M | $228.0M |
| Cash and investments | $58.2M | $41.3M | $47.3M | $128.6M | $227.6M |
| Total debt | $3.5M | $3.6M | $3.7M | $3.8M | $3.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 15, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
All 322 Immuneering Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.